IPO planned by Kantipur Pharmaceuticals, with Muktinath Capital serving as sale manager
The IPO process has begun at Kantipur Pharmaceuticals Lab. Muktinath Capital has been designated by the firm as the sales manager in order to move on with the share offering procedure.
The deal was signed by Kabindra Dhwaj Joshi, the chief executive officer of Muktinath Capital, and Navraj Paudyal, the director of Kantipur Pharmaceuticals Lab, during an event held at the company's corporate office in Lalitpur.
The public will purchase 11 million common shares, or 14.86 percent of the outstanding capital, from the corporation. Since its founding in 2018, the company has produced and distributed dietary supplements, conducted research on veterinary medications, and received a registration certificate for manufacturing and marketing from the Department of Medicines.
As of right now, the Department of Medicines has given the company production license for 61 medications, 13 of which have sales and distribution certifications and are being sold and distributed domestically. The business also stated that it is currently applying for sales and distribution licenses for more medications.
In addition, the company has been manufacturing and marketing twenty-one other dietary supplements. The company is the first in the pharmaceutical sector to provide shares to the general public under the veterinary pharmaceutical industry. Its primary goal is to improve the health of animals in Nepal and beyond.
